Swedish Orphan Biovitrum AB Unsponsored American Depositary Receipt Repr 1-2 shs Aktie 125596592 / US8703212055
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
|
15.12.2025 07:38:20
|
Sobi To Acquire Arthrosi Therapeutics
(RTTNews) - Swedish Orphan Biovitrum AB (SOBI.ST) has entered into an acquisition agreement with Arthrosi Therapeutics, which was invested in and incubated by Viva Biotech Holdings. Sobi will pay up to $1.5 billion in total transaction value, including an upfront payment at closing of $950 million, and contingent consideration of up to $550 million. The company said the acquisition strengthens Sobi's gout franchise by adding pozdeutinurad, an investigational once-daily oral URAT inhibitor currently being evaluated in two fully recruited global Phase 3 clinical studies for the potential management of progressive and tophaceous gout.
Arthrosi has also entered into new statement of work with the Viva Biotech's CDMO business unit for the supply of active pharmaceutical ingredient, and the Group expects to continue its business cooperation with Arthrosi.
Guido Oelkers, CEO of Sobi, said: "Pozdeutinurad has the potential to become the therapy of choice for patients who have progressive gout with persistent and unresolved symptoms despite first-line therapy. The product has the potential to materially accelerate our growth until the mid 2030s, and beyond."
Sobi projects the acquisition to be highly accretive to mid- to long-term growth and margin trajectory.
For More Such Health News, visit rttnews.com.
Nachrichten zu Swedish Orphan Biovitrum AB Unsponsored American Depositary Receipt Repr 1-2 shs
Analysen zu Swedish Orphan Biovitrum AB Unsponsored American Depositary Receipt Repr 1-2 shs
KI-Hype – Wer profitiert? Wall Street Live mit Tim Schäfer
Welche Unternehmen profitieren vom KI-Hype – auch abseits der bekannten Tech-Giganten wie Nvidia, Microsoft oder Alphabet?
Im heutigen Interview analysiert Tim Schaefer @TimSchaeferMedia die zweite Reihe der KI-Profiteure: Energieversorger, Rechenzentren, Kühlung, Infrastruktur & Software. Denn wo grosse Sprachmodelle und KI-Anwendungen betrieben werden, braucht es vor allem eins: Strom, Speicher und Struktur.
💡 Welche Unternehmen profitieren indirekt vom KI-Boom?
💡 Welche Branchen bieten stabile Dividenden bei solider Bewertung?
Eine spannende Analyse für alle, die KI-Investments breiter denken wollen.
👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Aktien in diesem Artikel
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
SMI stärker -- DAX freundlich -- Asiens Börsen verlierenDer heimische Aktienmarkt notiert im Plus, während der deutsche Aktienmarkt Gewinne verzeichnet. Asiens Börsen geben zum Wochenbeginn nach.